通过两种APC/C化学抑制剂对线粒细胞退出的协同阻断
Katharine L Sackton1, Nevena Dimova1, Xing Zeng1
11] Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115, USA [2].
Nature
|August 27, 2014
概括
癌症治疗可以向促进酶复合体/循环体 (APC/C),这是一个调节细胞分裂的蛋白质机器. 一种新的抑制剂,apcin,通过破坏关键蛋白相互作用来阻断APC/C活性,提供了一个潜在的治疗策略.
科学领域:
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 亚纳酶促进复合体/循环体 (APC/C) 是一个关键的E3泛酸酶,调节了线粒体的退出.
- APC/C活动对于细胞周期进展至关重要,其调节失调与癌症有关.
- 在APC/C中,共受体Cdc20需要向securin和cyclin B1等基质进行降解.
研究的目的:
- 研究针对癌症治疗APC/C的新型治疗策略.
- 通过破坏多个蛋白质-蛋白质相互作用来探索APC/C依赖蛋白质解酶的协同抑制.
- 识别和描述抑制APC/C功能的小分子.
主要方法:
- 一种新型APC/C抑制剂apcin的鉴定和表征.
- 使用X射线晶体学对apcin-Cdc20复合物的结构分析.
- 评估apcin与其他APC/C抑制剂结合的协同效应.
主要成果:
- 阿普辛与Cdc20结合,竞争性地抑制含有破坏盒 (D-box) 的基质的无处不在.
- 结构数据显示apcin占据了Cdc20上的D盒绑定口袋.
- 同时服用阿普辛与托西尔-l-阿尔金因甲基,可以协同抑制APC/C活性和线性退出.
结论:
- 在APC/C-Cdc20基质复合体内同时破坏多个蛋白质-蛋白质相互作用是抑制APC/C的有效策略.
- 阿普辛是癌症治疗的有前途的治疗剂,它通过阻断线粒细胞的退出来治疗癌症.
- 针对APC/C等蛋白质机器,为癌症药物开发提供了一个新的途径.
相关概念视频
Separation of Sister Chromatids
3.6K
At the transition from prophase to metaphase, there is a reduction in cohesion along the chromosomal arms, resulting in the resolution of sister chromatids. However, residual cohesin connections remain to hold the sister chromatids together until the transition from metaphase to anaphase. The residual connection prevents any premature separation of sister chromatids, blocking the risks of aneuploidy within the daughter cells.
At the onset of anaphase, separase, a proteolytic enzyme, is...
At the onset of anaphase, separase, a proteolytic enzyme, is...
3.6K
Anaphase Promoting Complex
2.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.5K
Anaphase Promoting Complex
1.5K
1.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity
4.3K
4.3K
Drugs that Destabilize Microtubules
3.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.1K


